<DOC>
	<DOC>NCT00036270</DOC>
	<brief_summary>To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.</brief_summary>
	<brief_title>Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated. Stage T13 N02 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered. Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria: Inflammatory breast cancer Histologically positive supraclavicular nodes Ulceration/infiltration of local skin metastasis Neoadjuvant chemotherapy Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion ER and PR negative primary tumor or ER/PR unknown status.</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>